What is Medpace Holdings, Inc.'s SG&A?

Medpace Holdings, Inc. (MEDP) reported SG&A of $48.1M in Q2 2026.

How has Medpace Holdings, Inc.'s SG&A changed year-over-year?

Medpace Holdings, Inc.'s SG&A increased by 3.1% year-over-year, from $46.66M to $48.1M.

What is the long-term trend for Medpace Holdings, Inc.'s SG&A?

Over 4 years (2021 to 2025), Medpace Holdings, Inc.'s SG&A has grown at a 16.2% compound annual growth rate (CAGR), from $108.42M to $197.56M.

Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.

Medpace Holdings, Inc. (MEDP) SG&A

Screener

SG&A at other companies

Thermo Fisher ScientificTMO

$1.91B—

Labcorp HoldingsLH

$577.2M-0.4%

IQVIAIQV

$574M+12.8%

Fortrea Holdings Inc.FTRE

$102.1M-18.2%

Lifecore Biomedical, Inc.LFCR

$7.97M—

Simulations PlusSLP

$4.68M-23.7%

Segments

By segment

See full

Reportable Segment$48.1M+3.1%

Other financials

Income statement

See full

Revenue$707.3M+17.2%

Operating income$146.8M+16.2%

Net income$121.4M+34.5%

EPS (diluted)$4.25+37.1%

Balance sheet

See full

Cash & equivalents$502.7M+985%

Total debt$144.1M-3.8%

Total equity$433.9M+152%

Total assets$2.1B+30.9%

Cash flow

See full

Operating cash flow$162.0M+9.1%

CapEx$23.9M+291%

Free cash flow$138.1M-3.0%

Valuation

See full

Market cap$16.41B+35.7%

Enterprise value$16.05B+31.6%

P/E33.4×+4.5×

P/S5.9×+0.5×

Profitability

See full

Operating margin21%-0.4pp

Net margin17.7%-1.1pp

FCF margin25.4%-0.6pp

Returns & leverage

See full

Return on equity162.2%+72.8pp

Debt / equity0.3×-0.5×

Current ratio0.7×+0.3×

Where this comes from

Reported directly by Medpace Holdings, Inc. in its filing.

Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.

The source filing: Medpace Holdings, Inc.’s 10-Q, filed July 23, 2026.

Filed: Jul 23, 2026, 4:03 PM EDT
Fiscal quarter: Q2 FY2026
Calendar quarter: Q2 2026
Accession: 0001668397-26-000025

(Amounts in thousands, except per share amounts)	Three Months Ended June 30, 2026	Three Months Ended June 30, 2025	Six Months Ended June 30, 2026	Six Months Ended June 30, 2025
Direct service costs, excluding depreciation and amortization	202,555	185,826	400,829	363,642
Reimbursed out-of-pocket expenses	303,139	237,472	615,143	439,876
Total direct costs	505,694	423,298	1,015,972	803,518
Selling, general and administrative	48,103	46,664	96,020	104,561
Depreciation	6,555	6,777	13,306	13,471
Amortization	155	237	310	473
Total operating expenses	560,507	476,976	1,125,608	922,023
Income from operations	146,824	126,335	288,327	239,858

Item 1. Financial Statements (unaudited)

FAQ

What is Medpace Holdings, Inc.'s SG&A?: Medpace Holdings, Inc. (MEDP) reported SG&A of $48.1M in Q2 2026.
How has Medpace Holdings, Inc.'s SG&A changed year-over-year?: Medpace Holdings, Inc.'s SG&A increased by 3.1% year-over-year, from $46.66M to $48.1M.
What is the long-term trend for Medpace Holdings, Inc.'s SG&A?: Over 4 years (2021 to 2025), Medpace Holdings, Inc.'s SG&A has grown at a 16.2% compound annual growth rate (CAGR), from $108.42M to $197.56M.
What does SG&A mean?: Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.

Ask your AI about Medpace Holdings, Inc.'s sg&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Medpace Holdings, Inc. MEDP SG&A

SG&A at other companies

Segments

By segment

Other financials

Income statement

Balance sheet

Cash flow

Valuation

Profitability

Returns & leverage

Where this comes from

FAQ

Ask your AI about Medpace Holdings, Inc.'s sg&a.